Edesa Biotech reports positive exploratory data for paridiprubart in acute kidney injury

Edesa Biotech (NASDAQ:EDSA) announced favorable exploratory findings for its lead therapeutic candidate, paridiprubart, in patients suffering from acute kidney injury (AKI) and concurrent respiratory distress.

The data, presented on June 5, 2026, at the 63rd European Renal Association (ERA) Congress in Glasgow, Scotland, provide preliminary evidence of the drug's potential efficacy in a high-risk population that currently lacks targeted pharmacological treatments.

The findings are derived from a post hoc analysis of 101 hospitalized patients originally enrolled in the company’s Phase 2 and Phase 3 studies of acute respiratory distress syndrome (ARDS).

The patient cohort demonstrated that paridiprubart, when administered alongside standard of care, was associated with an adjusted 33% 28-day mortality rate, compared to 49% for those receiving the placebo.

This represents a 32% relative reduction in the risk of death.

In addition to mortality benefits, the analysis showed improvements in secondary kidney-specific outcomes.

Patients treated with paridiprubart exhibited a reduction in the incidence of major adverse kidney events (MAKE30) compared to the placebo group.

The study reported that the drug maintained a safety profile consistent with prior clinical exposures, with adverse event rates comparable to those observed in the placebo arm.

Paridiprubart is a first-in-class monoclonal antibody designed to selectively inhibit Toll-like receptor 4 (TLR4), a protein implicated in the hyperinflammatory cascade that triggers and amplifies both lung and kidney damage.

By targeting this mechanism, Edesa aims to provide a host-directed therapeutic that functions independently of the specific pathogen or insult causing the initial injury.

While the results are encouraging, Edesa emphasized that these analyses are exploratory and were not prespecified in the original trial designs.

As such, the company noted that the data are intended to generate hypotheses and that prospective, confirmatory studies will be required to formally establish the efficacy of paridiprubart as a treatment for acute kidney injury.